{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.53","value":"25.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"587"}],"units":"Participants"}],"description":"Time between first dose and when a TEAE for peripheral neuropathy was reported. The mean is the univariate mean without adjusting for censoring. The treatment duration was used for censored participants.","dispersionType":"Standard Deviation","groups":[{"description":"Lenalidomide administered orally, 25 mg daily (QD) for the first 21 days of each 28-day cycle. Pulse dexamethasone administered orally, 40 mg daily on Days 1-4, 9-12, and 17-20 for each 28-day cycle during Cycles 1 to 4 (approximately months 1-4). Beginning with Cycle 5 (approximately month 5), a maintenance dose of dexamethasone (40 mg QD) was administered on Days 1 to 4 of each 28-day cycle.","id":"OG000","title":"Lenalidomide Plus Dexamethasone"}],"paramType":"MEAN","populationDescription":"Safety population","reportingStatus":"POSTED","timeFrame":"up to 124 weeks","title":"Time to First Peripheral Neuropathy Treatment-Emergent Adverse Event (TEAE)","type":"SECONDARY","unitOfMeasure":"weeks"}